Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus

Sung, Min Je; Lim, Tae-Young; Jeon, Mi Young; Lee, Hye Won; Kim, Seung Up; Ahn, Sang Hoon; Han, Kwang Hyub; Park, Jun Yong

doi:10.5009/gnl19126

Cited by 25 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some studies, a significantly higher prevalence of sarcopenia in men [ 48 , 63 , 64 ] or women [ 65 , 70 ] was reported. However, other studies [ 47 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 66 ] did not find any difference in gender distribution among T2DM with sarcopenia.…”

Section: Resultsmentioning

confidence: 79%

See 1 more Smart Citation

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

et al. 2021

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) represents a major health burden for the elderly population, affecting approximately 25% of people over the age of 65 years. This percentage is expected to increase dramatically in the next decades in relation to the increased longevity of the population observed in recent years. Beyond microvascular and macrovascular complications, sarcopenia has been described as a new diabetes complication in the elderly population. Increasing attention has been paid by researchers and clinicians to this age-related condition—characterized by loss of skeletal muscle mass together with the loss of muscle power and function—in individuals with T2DM; this is due to the heavy impact that sarcopenia may have on physical and psychosocial health of diabetic patients, thus affecting their quality of life. The aim of this narrative review is to provide an update on: (1) the risk of sarcopenia in individuals with T2DM, and (2) its association with relevant features of patients with T2DM such as age, gender, body mass index, disease duration, glycemic control, presence of microvascular or macrovascular complications, nutritional status, and glucose-lowering drugs. From a clinical point of view, it is necessary to improve the ability of physicians and dietitians to recognize early sarcopenia and its risk factors in patients with T2DM in order to make appropriate therapeutic approaches able to prevent and treat this condition.

show abstract

Section: Resultsmentioning

confidence: 79%

“…In epidemiological studies, the prevalence of sarcopenia in T2DM has a wide range, varying from 7% to 29.3% in different populations [ 6 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ], ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The cross‐sectional CT images at L3 were analysed using commercially available CT software (Rapidia 2.8; INFINITT) to determine the skeletal muscle and abdominal adipose tissue areas. The following tissue Hounsfield unit (HU) thresholds were employed: −29 to 150 HU for skeletal muscle, −190 to −30 HU for subcutaneous adipose tissue and −150 to −50 HU for visceral adipose tissue 9,25,26 . The three body composition areas (cm 2 ) were divided by the square of the height in meters (m 2 ) to obtain the SMI, visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI) in units of cm 2 /m 2 11,27,28 .…”

Section: Methodsmentioning

confidence: 99%

Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease

Hsieh

Joo

Koo

et al. 2020

Liver International

View full text Add to dashboard Cite

Background & Aim Anthropometric data are associated with nonalcoholic fatty liver disease (NAFLD) development and progression. We investigated whether the quantity and quality of muscle and visceral fat assessed by computed tomography (CT) are associated with fibrosis severity in NAFLD. Methods In a prospective biopsy‐confirmed NAFLD cohort of 521 patients, we measured skeletal muscle index (SMI), muscle attenuation (MA) and visceral adipose tissue index (VATI) via CT. Low skeletal muscle mass (LSMM) was defined using previously validated cut‐offs. Myosteatosis and visceral adiposity were defined as the lowest and highest quartile, respectively. Significant fibrosis was defined as F2‐F4 in liver histology. Results Patients with significant fibrosis had lower SMI and MA and higher VATI than those without. The significant fibrosis prevalence was significantly higher in subjects with LSMM (45.1% vs 30.8%, P = .005), myosteatosis (46.1% vs 29.7%, P = .001) and visceral adiposity (46.9% vs 29.9%, P = .001) than those without. The significant fibrosis risk increased with increasing numbers of body composition components (24.5%, 35.6%, 53.0% and 72.7% in patients with 0, 1, 2 and 3 components respectively). Multivariable analysis revealed that LSMM (OR, 1.72; 95% CI, 1.05‐2.84), myosteatosis (OR, 1.65; 95% CI, 1.01‐2.68) and visceral adiposity (OR, 1.75; 95% CI, 1.09‐2.83) were independent predictors of significant fibrosis. Subjects with sarcopenia had a higher risk of significant fibrosis (OR, 2.17; 95% CI, 1.03‐4.56). Conclusion Muscle alterations and visceral adiposity assessed by CT are associated with significant fibrosis in NAFLD. LSMM and myosteatosis have additive values in prediction of significant fibrosis.

show abstract

“…AAV patients, who had serious medical conditions mimicking AAV or enabling ANCA false-positivity, such as chronic liver diseases, coexisting malignancies, serious infections, and drugs at the time of diagnosis, were excluded from this study. For controls, the medical records of general people, who had consecutively visited Severance Executive Healthcare Clinic in Severance Hospital, a university-a liated tertiary care hospital, for a comprehensive medical health check-up, were also reviewed [20]. And, 344 age-and gender-matched people without any serious medical condition were included in this study as controls.…”

Section: Study Subjectsmentioning

confidence: 99%

Clinical implication of metabolic syndrome in nonobese patients with antineutrophil cytoplasmic antibody-associated vasculitis

Lee

Kwon

Pyo

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Objective: We investigated the prevalence of metabolic syndrome (MetS) in all or nonobese patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and compared it with age- and gender-matched controls. Also, we assessed the effect of variables at diagnosis on the risk of cardiovascular disease (CVD) in all or nonobese AAV patients. Methods: In this study, 173 AAV patients and 344 controls were included and MetS was defined by the National Cholesterol Education Program Adults Treatment Panel III criteria. The obesity based on body mass index (BMI) was defined as BMI ≥ 25 kg/m2. The follow-up duration was defined as the period from diagnosis to the last visit or to each poor outcome occurrence.Results: The median age of AAV patients was 58.7 years and 57 patients were men. The prevalence of MetS was 50.9% in all AAV patients and 46.5% in nonobese AAV patients, which were significantly higher than 37.8% in all controls and 28.2% in nonobese controls. In the Kaplan-Meier survival analysis, Mets at diagnosis significantly reduced the cumulative CVD-free survival rate in both all and nonobese AAV patients. In the multivariable Cox hazards model analysis, CVD during follow-up was significantly associated with both BVAS (HR 1.159) and MetS at diagnosis (HR 9.036) in nonobese AAV patients.Conclusions: The prevalence of MetS at diagnosis in all or nonobese AAV patients was significantly higher than those in all or nonobese controls. Furthermore, both BVAS and MetS at diagnosis increased the risk of CVD in nonobese AAV patients.

show abstract

Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus

Cited by 25 publications

References 38 publications

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease

Clinical implication of metabolic syndrome in nonobese patients with antineutrophil cytoplasmic antibody-associated vasculitis

Contact Info

Product

Resources

About